Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox®)

• DOI: 10.7314/apjcp.2013.14.3.2131
• Publication Date: 2013-08-08T05:33:45Z
• Authors: Nipon Khemapech; S. Oranratanaphan; W. Termrungruanglert; R. Lertkhachonsuk; A. Vasurattana
• Keywords: Carboplatin; Fallopian tube cancer; Fallopian tube; Mucositis; Refractory (planetary science)

Background: To evaluate the efficacy and safety of distearoylphosphatidylcholine pegylated liposomal doxorubicin (DPLD) combined with carboplatin for treatment platinum resistant or refractory epithelial ovarian cancer (EOC) fallopian tube cancer. Materials Methods: A retrospective analysis women who received DPLD recurrent EOC in King Chulalongkorn Memorial Hospital Thailand from January 2006 to August 2011 was conducted. Patients were identified medical records data on demographic factors, stage, histology, surgical findings, cytoreduction status, prior chemotherapies abstracted. The toxicity DPLD/carboplatin evaluated. Progression-free (PFS) overall survival (OS) estimated by Kaplan-Meier method. Results: total 65 patients, 64 1 cancer, enrolled. given an average 4.46 cycles per patient a 273 cycles. Among evaluable 0% achieved CR, 7.69% PR, 15.4% SD 76.% PD. response rate 23.1%. With median follow-up 27.4 months, progression-free 36 patients months 8.76 respectively. In aspect side effects, palmar-plantar erythrodysesthesia (PPE) occurred 33.3% (Grade I 22.2%, Grade II 11.1%) mucositis 41.7% 27.8%, 13.9%) all cycles, 2. Anemia, leukopenia thrombocytopenia 58.3% 41.7%, 16.7%), 66.7% 47.2%, 19.4%), 22.2% 16.6%, 5.56%) cycle respectively, mostly Conclusions: DPLD, second-generation PLD drug every 4 weeks, is effective has low platinum-resistant